Angiotensin II induced inflammation in the kidney and in the heart of double transgenic rats

[1]  F. Luft,et al.  Workshop: mechanisms and cardiovascular damage in hypertension. , 2001, Hypertension.

[2]  D. Sorescu,et al.  Modulation of Protein Kinase Activity and Gene Expression by Reactive Oxygen Species and Their Role in Vascular Physiology and Pathophysiology , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[3]  M. Ushio-Fukai,et al.  Reactive oxygen species as mediators of angiotensin II signaling , 2000, Regulatory Peptides.

[4]  D. Ganten,et al.  Angiotensin II (AT(1)) receptor blockade reduces vascular tissue factor in angiotensin II-induced cardiac vasculopathy. , 2000, The American journal of pathology.

[5]  Qingbo Xu,et al.  Mechanical stress-initiated signal transductions in vascular smooth muscle cells. , 2000, Cellular signalling.

[6]  G. Wallukat,et al.  AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor. , 2000, Circulation.

[7]  D. Ganten,et al.  NF-κB Inhibition Ameliorates Angiotensin II–Induced Inflammatory Damage in Rats , 2000 .

[8]  D. Ganten,et al.  NF-kappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. , 2000, Hypertension.

[9]  E. Schiffrin,et al.  Ang II-stimulated superoxide production is mediated via phospholipase D in human vascular smooth muscle cells. , 1999, Hypertension.

[10]  R. Dietz,et al.  Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-kappaB and induces tissue factor and PAI-1 expression: a potential link to accelerated arteriosclerosis. , 1999, Circulation.

[11]  A. Malik,et al.  Inhibition of NF-kappaB activation by pyrrolidine dithiocarbamate prevents In vivo expression of proinflammatory genes. , 1999, Circulation.

[12]  Y. Wang,et al.  Inhibition of nuclear factor-κB activation reduces cortical tubulointerstitial injury in proteinuric rats , 1999 .

[13]  P. Libby,et al.  Angiotensin induces inflammatory activation of human vascular smooth muscle cells. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[14]  C. Scheidereit,et al.  The Bcl-3 oncoprotein acts as a bridging factor between NF-κB/Rel and nuclear co-regulators , 1999, Oncogene.

[15]  S. Moncada,et al.  Inhibition of nitric oxide synthase as a potential therapeutic target. , 1999, Annual review of pharmacology and toxicology.

[16]  D. Ganten,et al.  Hypertension-induced end-organ damage : A new transgenic approach to an old problem. , 1999, Hypertension.

[17]  D. Ganten,et al.  Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. , 1999, Hypertension.

[18]  J. Egido,et al.  ACE inhibitor quinapril reduces the arterial expression of NF-kappaB-dependent proinflammatory factors but not of collagen I in a rabbit model of atherosclerosis. , 1998, The American journal of pathology.

[19]  G. Remuzzi,et al.  Pathophysiology of progressive nephropathies. , 1998, The New England journal of medicine.

[20]  W R Taylor,et al.  Role of NADH/NADPH oxidase-derived H2O2 in angiotensin II-induced vascular hypertrophy. , 1998, Hypertension.

[21]  S. Klahr.  The role of L‐arginine in hypertension and nephrotoxicity , 1998, Current opinion in nephrology and hypertension.

[22]  K. Mihara,et al.  Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. , 1998, Circulation.

[23]  F. Luft,et al.  ICAM-1 antisense oligodesoxynucleotides prevent reperfusion injury and enhance immediate graft function in renal transplantation. , 1998, Kidney international.

[24]  B. Altura,et al.  Pyrrolidine dithiocarbamate attenuates alcohol-induced leukocyte-endothelial cell interaction and cerebral vascular damage in rats: possible role of activation of transcription factor NF-kappaB in alcohol brain pathology. , 1998, Alcohol.

[25]  J. Egido,et al.  Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 synthesis. , 1998, Journal of immunology.

[26]  H Ishii,et al.  Xanthine oxidase activity associated with arterial blood pressure in spontaneously hypertensive rats. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[27]  F. Luft,et al.  The renin-angiotensin system in the vessel wall , 1998, Basic Research in Cardiology.

[28]  S. Klahr,et al.  Enalapril decreases nuclear factor κB activation in the kidney with ureteral obstruction: Rapid Communication , 1997 .

[29]  T. Ogihara,et al.  In vivo transfection of cis element “decoy” against nuclear factor- κB binding site prevents myocardial infarction , 1997, Nature Medicine.

[30]  B. Berk,et al.  Angiotensin II signal transduction in vascular smooth muscle: role of tyrosine kinases. , 1997, Circulation research.

[31]  M. Karin,et al.  Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. , 1997, The New England journal of medicine.

[32]  S. Klahr,et al.  Rapid communication. Enalapril decreases nuclear factor kappa B activation in the kidney with ureteral obstruction. , 1997, Kidney international.

[33]  G. Remuzzi,et al.  Understanding the nature of renal disease progression. , 1997, Kidney international.

[34]  C. Scheidereit,et al.  The NF-κB/Rel and IκB gene families: mediators of immune response and inflammation , 1996, Journal of Molecular Medicine.

[35]  J. Redondo,et al.  Transcriptional up-regulation of intracellular adhesion molecule-1 in human endothelial cells by the antioxidant pyrrolidine dithiocarbamate involves the activation of activating protein-1. , 1996, Journal of immunology.

[36]  C. Patterson,et al.  Suppression of Interleukin-1β-induced Nitric-oxide Synthase Promoter/Enhancer Activity by Transforming Growth Factor-β1 in Vascular Smooth Muscle Cells , 1996, The Journal of Biological Chemistry.

[37]  C. Sen,et al.  Antioxidant and redox regulation of gene transcription , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[38]  C. Patterson,et al.  Suppression of interleukin-1beta-induced nitric-oxide synthase promoter/enhancer activity by transforming growth factor-beta1 in vascular smooth muscle cells. Evidence for mechanisms other than NF-kappaB. , 1996, The Journal of biological chemistry.

[39]  C. Scheidereit,et al.  The NF-kappa B/Rel and I kappa B gene families: mediators of immune response and inflammation. , 1996, Journal of molecular medicine.

[40]  U. Sieben,et al.  STRUCTURE, REGULATION AND FUNCTION OF NF-1d3 , 1994 .

[41]  G. Franzoso,et al.  Structure, regulation and function of NF-kappa B. , 1994, Annual review of cell biology.

[42]  U. Zabel,et al.  Nuclear uptake control of NF‐kappa B by MAD‐3, an I kappa B protein present in the nucleus. , 1993, The EMBO journal.

[43]  D. Männel,et al.  Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells , 1992, The Journal of experimental medicine.

[44]  D. Baltimore,et al.  NF-κB: A pleiotropic mediator of inducible and tissue-specific gene control , 1989, Cell.

[45]  D. Baltimore,et al.  NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control. , 1989, Cell.